News & Events

Public Disclosures

Vivli aims to advance human health through clinical research data sharing. One of the key ways we support this is through the Vivli platform, which facilitates data sharing for research teams working on a range of topics. These tables provide details of approved research proposals that have published or presented their results.

Top publications by PubMed citations
YearData Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
20236104Pratik Sinha Washington University Heterogeneous treatment effects in molecular phenotypes of sepsisSinha, P., Kerchberger, V.E., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L. and Langelier, C.R., 2023. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. The Lancet Respiratory Medicine.

Doi:10.1016/S2213-2600(23)00237-0
Lilly
81
20215096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicineSynthetic lethality-mediated precision oncology via the tumor transcriptome. Lee, Joo Sang et al.
Cell, Volume 184, Issue 9, 2487 - 2502.e13.

doi: 10.1016/j.cell.2021.03.030
Tempus AI, Inc.
69
20234113Lesley Inker Tufts Medical Center Chronic Kidney Disease Epidemiology - Clinical Trials Consortium (CKD-EPI CT)Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J. and Goicoechea, M., 2023. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, pp.1-10.

Doi: 10.1038/s41591-023-02418-0
GlaxoSmithKline, Takeda
54
20204540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trialWilkinson, C., Wu, J., Searle, S.D. et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18, 401 (2020).

doi: 10.1186/s12916-020-01870-w
Daiichi Sankyo
54
20237875Marco ValgimigliCardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AÃ…, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105.

doi: 10.1016/j.jacc.2023.04.051
Sanofi
51
20224116Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisVeroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012.

doi: 10.1136/bmjopen-2021-053012
AbbVie
50
20227074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesRomiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29.

doi: 10.1055/s-0042-1756355
Boehringer Ingelheim
50
20204116Sharon StrausSt. Michael's HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisVeroniki AA, Ashoor H, Rios P, Seitidis G, Mavridis D, Holroyd-Leduc J, Straus S, Tricco A. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):455.

doi: 10.1002/14651858.CD202001
AbbVie
50
20205895, 6117Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersConcomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland and Michael J. Sorich.
Clin Cancer Res October 15 2020 (26) (20) 5487-5493;

doi: 10.1158/1078-0432.CCR-20-1876
Roche
49
20224329Shomron Ben-HorinSun Yatsen 1st affiliated HospitalEfficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseShomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology, 2021, ISSN 0016-5085.

doi: 10.1053/j.gastro.2021.10.037
AbbVie, Biogen, Johnson & Johnson, Takeda, UCB
48

Top publications by Altmetrics score
YearData Request IDLead InvestigatorInstitutionResearch Proposal TitlePublic DisclosureData Contributor(s)Altmetric ScorePubMed Citation Total
20259813Sameer JauharKing's College LondonConducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressantsKalfas, Michail, Tsapekos, Dimosthenis, Butler, Matthew, McCutcheon, Robert A., Pillinger, Toby, Strawbridge, Rebecca, Bhat, Bhagyashree Bhaskar, Haddad, Peter M., Cowen, Philip J., Howes, Oliver D., Joyce, Dan W., Nutt, David J., Baldwin, David S., Pariante, Carmine M., Lewis, Gemma, Young, Allan H., Lewis, Glyn, Hayes, Joseph F. and Jauhar, Sameer. "Incidence and Nature of Antidepressant Discontinuation Symptoms." JAMA Psychiatryvol. , no. , Jul. 2025, pp.

https://doi.org/10.1001/jamapsychiatry.2025.1362
Lilly, Lundbeck, Pfizer, Takeda
N/A
20236544Angela WuUniversity of OxfordInvestigating the association between smoking cessation and mental health in people with and without psychiatric disordersWu, A.D., Gao, M., Aveyard, P. and Taylor, G., 2023. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders. JAMA Network Open, 6(5), pp.e2316111-e2316111.

Doi: 10.1001/jamanetworkopen.2023.16111
Pfizer
17
20255959John Dennis University of Exeter Medical School Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesDennis, J.M., Young, K.G., Cardoso, P., Güdemann, L.M., McGovern, A.P., Farmer, A., Holman, R.R., Sattar, N., McKinley, T.J., Pearson, E.R. and Jones, A.G., 2025. A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study. The Lancet.

Doi: 10.1016/S0140-6736(24)02617-5
Boehringer Ingelheim, Takeda
N/A
20237875Marco ValgimigliCardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AÃ…, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105.

doi: 10.1016/j.jacc.2023.04.051
Sanofi
51
20257810Diego Chowell Icahn School of Medicine at Mount Sinai Machine learning model to predict cancer immunotherapy responseYoo, S.K., Fitzgerald, C.W., Cho, B.A., Fitzgerald, B.G., Han, C., Koh, E.S., Pandey, A., Sfreddo, H., Crowley, F., Korostin, M.R. and Debnath, N., 2025. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nature Medicine, pp.1-12.

Doi: 10.1038/s41591-024-03398-5
Roche
N/A
20259492, 8697 David McAllister University of Glasgow Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditionsHanlon P., Butterly, E., Wei L. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes. 2025. A Network Meta-Analysis. JAMA.

Doi: 10.1001/jama.2024.27402
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB
20237743Caroline Quach CHU Sainte-Justine Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-AnalysisKiely, M., Tadount, F., Lo, E., Sadarangani, M., Wei, S.Q., Rafferty, E., Quach, C. and MacDonald, S.E., 2023. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health.

Doi: 10.1136/jech-2023-220781
Sanofi
4
20225933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisDaraghmeh DN, Hopkins AM, King C, Abuhelwa AY, Wechalekar MD, Proudman SM, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2022 Jun 22:keac357.

doi : 10.1093/rheumatology/keac357
Roche
2
20235951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismMaria A de Winter, Harry R Büller, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Gary E Raskob, Henrik T Sørensen, Frank L J Visseren, Philip S Wells, Jannick A N Dorresteijn, Mathilde Nijkeuter, VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. European Heart Journal, 2023;. ehac776.

doi: 10.1093/eurheartj/ehac776
Boehringer Ingelheim, Daiichi Sankyo
18
20237164Jörg EllingerUniversity Hospital BonnEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaSaal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology.

doi: 10.1001/jamaoncol.2023.1822
Roche
13

Public disclosures by year 

T1D exercise data RFP from Helmsley Charitable Trust due the end of this month

The Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 Diabetes Program has launched an initiative to support innovative and practicable solutions to help people with type 1 diabetes (T1D) exercise safely and to improve their quality of life. To help address knowledge gaps about the effect of exercise on T1D, Helmsley supported a research collaboration centered on two large observational exercise studies in people with T1D: one in adults (T1-DEXI) and one in children (T1-DEXIP). More than 500 people took part in the adult study, and another 250 in the pediatric study. Both studies were recruited and conducted fully remotely by design, enabling full monitoring and data collection which was unimpeded by COVID-19 pandemic restrictions.

The data from these studies include information about types of physical activity, heart rate, insulin use, CGM, diet, and genetics. The research collaboration collected and organized the observational data to maximize interoperability, and Helmsley has partnered with Vivli to make the data from T1-DEXI and T1-DEXIP publicly available. Sharing study data publicly will enable a range of researchers to access and explore the data from a variety of perspectives and research specialties.

In addition to facilitating public access through the Vivli platform, Helmsley has also opened a request for proposals (RFP) to support researchers, clinicians, and data scientists interested in analyzing the data and testing novel solutions in people with T1D. The RFP aims to fund projects that will improve the understanding of how exercise impacts T1D and that will provide people with T1D and their healthcare providers practical management solutions and clinical guidelines. The overarching purpose of this initiative is to move real-world data towards real-world solutions.

Concept notes for the RFP are due by April 30, 2023, and full proposals will be invited for submission later in 2023. Researchers interested in exploring the T1D dataset on Vivli in order to prepare concept notes for submission can search data publicly available through Vivli’s search portal, and submit a data request using the standard process. Complete information about the RFP, including key dates and submission criteria, is available on The Helmsley Charitable Trust site.

Deniz Dalton, Program Officer in T1D at Helmsley, said, “People with T1D face many burdensome challenges in their daily lives, including complex decisions around exercise, diet, monitoring glucose levels, and administering insulin. We are excited to make this data publicly available and to launch this RFP, to advance the understanding of how exercise affects glucose management, and ultimately to help create real-world solutions to challenges faced by people with T1D around exercise.”

For more information, please watch Dalton’s presentation on this initiative at the Vivli 2022 Annual Meeting, or contact Vivli User Support directly at support@vivli.org with any questions